ABOS Nasdaq Earnings call
Acumen Pharmaceuticals, Inc. (ABOS) · Q2 2026 results
Share price: $2.29 · 2026-10-29
Results Q2 2026 vs Q1 2026 · previous quarter · published 12 Aug 2026 and 12 May 2026
Net loss widened on the previous quarter. Management sounded restrained, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2026
Net income -32.7M vs -20.7M
Net income -32.7M vs -41.0M in Q2 2025 and -20.7M last quarter.
2 · How management spoke
Restrained
Less upbeat than 77% of company calls
Answers to analysts: restrained, in line with the script.
Similar to last call.
3 · What stood out Nothing unusual flagged this period.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$2.29
close of 2026-10-29
Free cash flow 2023
−$0.0B
Free cash flow 2024
−$0.1B
Free cash flow 2025
−$0.1B
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“So it is a really robust innovation ecosystem right now in the space, and we think that will continue to accelerate both commercially with products being adopted and grown in...”
“A substantial body of evidence supports this hypothesis, and we are excited by the opportunity to evaluate that thesis in a well-powered, randomized Phase II study with clinically meaningful endpoints.”
“ACU401, in particular, achieved up to a 40-fold greater frontal cortex exposure in non-human primates and significant increase in exposures in deep brain regions.”
Full figures
USD · ROIC.AI fundamentals (NASDAQ:ABOS, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | ||
| Operating income | -32.6M | -21.1M | Loss widened | -41.8M | Loss narrowed |
| Net income | -32.7M | -20.7M | Loss widened | -41.0M | Loss narrowed |
| EPS | -0.45 | -0.33 | Loss widened | -0.68 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — | 12-mo loss | — |
Topics
Most discussed now
- New During the second quarter, its focus remained on disciplined execution as Acumen Pharmaceuticals advanced sabirnetug towards the highly…
- New Acumen Pharmaceuticals will also have the CDR Sum of Boxes, again, another cognitive functional endpoint familiar to the agency and others…
- A substantial body of evidence supports this hypothesis, and Acumen Pharmaceuticals is excited by the opportunity to evaluate that thesis…
- ALTITUDE-AD remains a critical test of Acumen Pharmaceuticals' central scientific thesis that selectively targeting synaptotoxic…
- Acumen Pharmaceuticals continues to be encouraged with the engagement of patients, caregivers, investigators, and study sites participating…
Faded since Q1 2026
- Dropped Including statements concerning Acumen Pharmaceuticals' financial outlook and expected business plans.
- Dropped Clear value proposition in terms of the risk-benefit profile
- Fading In the first quarter, Acumen Pharmaceuticals continued to advance sabirnetug through its Phase II ALTITUDE-AD trial, building on the…
- Fading Acumen Pharmaceuticals sees this disciplined progress is bringing us closer to a potentially differentiated treatment option with people…
Latest announcements
Official filings, newest first.
- Regulation FD disclosure · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Regulation FD disclosure; Other events · SEC 8-K
- Shareholder vote results · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Material agreement; Unregistered share sale; Regulation FD disclosure · SEC 8-K
- Regulation FD disclosure · SEC 8-K